Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881621 · ClinicalTrials.gov registry record · Phase 2
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00881621 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 17 participants.
The verdict
NCT00881621, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Patients are being asked to participate in this study who have locally advanced or metastatic pancreatic cancer (cancer of the pancreas that has spread to another part of the body) that has gotten worse after first-line chemotherapy. The purpose of this study is to see if the drugs, Capecitabine and Lapatinib (two chemotherapy agents), prolong survival and improve quality of life as compared to supportive care alone. Lapatinib in combination with a drug called capecitabine, has been approved by the Food and Drug Administration (FDA) for the treatment of metastatic breast cancer. It has not yet been approved to treat this type of cancer. Both of these drugs are pills. This research is being done because it is not known if the combination of Capecitabine and Lapatinib is better than supportive care alone for pancreatic cancer.
Interventions
- DRUG Lapatinib and Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00881621
The ClinicalTrials.gov registry entry for NCT00881621 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lapatinib and Capecitabine is the first listed.
NCT00881621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00881621 about?
NCT00881621 is a clinical study titled "Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer". Patients are being asked to participate in this study who have locally advanced or metastatic pancreatic cancer (cancer of the pancreas that has spread to another part of the body) that has gotten worse after first-line chemotherapy. The purpose of this study is to see if the drugs, Capecitabine an...
What is the current status of trial NCT00881621?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2009-08. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00881621?
The interventions under investigation include: Lapatinib and Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00881621?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.